Omega Diagnostics said it had successfully manufactured three validation batches of a test kit for HIV.
The Visitect CD4 devices were tested in India, Zimbabwe and the UK, the company said.
Results demonstrated that all three batches performed in line with design goal parameters.
'These validation batches prove we can manufacture at scale and are a requirement for obtaining a CE Mark,' Omega Diagnostics said.
'As previously communicated, we continue to make good progress and expect to complete internal verification work and external performance evaluation of venous whole blood samples during February.'
At 8:29am: (LON:ODX) Omega Diagnostics Group PLC share price was +0.5p at 13.75p